Wednesday, March 04, 2015 1:35:05 PM
The short interest information of the company was disclosed in the recent information. OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI), In a major positive the short interest in OncoGenex Pharmaceuticals Inc. – Common Shares plummeted by 20.7% or 89,935 shares. The final shorts are 1.7% of the total floated shares. The positions dropped from 434,273 shares on January 30,2015 to 344,338 on February 13,2015. Inculcating the per-day average trading of 180,040 shares, the days to cover are 2.
Shares of OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) rose by 1.1% in the past week and 14.18% for the last 4 weeks. In the past week, the counter has outperformed the S&P 500 by 1.38% and the outperformance increases to 8.24% for the last 4 weeks.
OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) made into the market gainers list with the shares advancing 7.88% or 0.19 points. Due to strong positive momentum, the stock ended at $2.6, which is also near the days high of $2.72. The stock began the session at $2.42 and the volume stood at 1,392,016 shares. The previous session had ended at $2.41. The 52-week high of the shares is $14.25 and the yearly low is $1.92. The company is a major component of the market with a cap of $55 million and is a highly liquid scrip with 21,281,000 shares in outstanding.
Recent ACHV News
- Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024 • GlobeNewswire Inc. • 07/09/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/09/2024 04:15:14 AM
- Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:07:23 PM
- Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 05/20/2024 09:01:27 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/17/2024 06:56:31 PM
- Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting • GlobeNewswire Inc. • 05/17/2024 12:00:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:08:41 PM
- Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 08:01:28 PM
- Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine • GlobeNewswire Inc. • 05/06/2024 03:16:04 PM
- Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024 • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update • GlobeNewswire Inc. • 03/28/2024 08:01:21 PM
- Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024 • GlobeNewswire Inc. • 03/14/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:49:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:43:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:41:19 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 09:16:29 PM
- Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission • GlobeNewswire Inc. • 02/29/2024 01:01:00 PM
- Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/27/2024 08:32:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 07:07:33 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM